Zabdeno (monovalent ebola virus vaccine) / J&J 
Welcome,         Profile    Billing    Logout  

9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zabdeno (monovalent ebola virus vaccine) / J&J
NCT04152486: Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Active, not recruiting
3
20426
RoW
Ad26.ZEBOV, MVA-BN-Filo vaccine
London School of Hygiene and Tropical Medicine, Epicentre, Ministère de la Santé de la RDC, Médecins Sans Frontières, France, Coalition for Epidemic Preparedness Innovations, Janssen Vaccines & Prevention B.V., Public Health England
Ebola Virus Disease
01/22
02/22
NCT02967003 / 2015-004139-11: Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Recruiting
3
5500
US, Europe, RoW
Ad26.ZEBOV, MVA-BN-Filo
Janssen Vaccines & Prevention B.V., Bavarian Nordic GmbH
Hemorrhagic Fever, Ebola
05/22
05/22
INGABO, NCT04556526: A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

Completed
3
4031
RoW
Ad26.ZEBOV, MVA-BN-Filo
Janssen Vaccines & Prevention B.V., Center for Family Health Research (CFHR), Coalition for Epidemic Preparedness Innovations, Emory University
Healthy
03/23
03/23
EBO-BOOST, NCT06126822: Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC

Not yet recruiting
3
624
RoW
Zabdeno® booster, Ervebo® booster
Institute of Tropical Medicine, Belgium, Institut National pour la Recherche Biomedicale (INRB)
Ebola Virus Disease
10/25
10/26
2017-004610-26: Evaluation the duration of the immune response of a late booster dose of a vaccine against Ebola virus disease - AD26.ZEBOV - in healthy adults previously immunised with investigational Ebola vaccine schedules.

Not yet recruiting
2
156
Europe
Ad26-ZEBOV, Suspension for injection
Clinical Trials and Research Governance (CTRG), University of Oxford, INNOVATE UK, Janssen UK
Ebola Virus Disease, Ebola virus disease (EVD), is a severe, often fatal disease in humans, spread by contact with body fluids., Diseases [C] - Virus Diseases [C02]
 
 
NCT02876328 / 2019-001308-39: Partnership for Research on Ebola VACcinations

Completed
2
4789
RoW
Ad26.ZEBOV, rHAd26, MVA-BN-Filo, MVA, MVA-mBN226B, rVSVΔG-ZEBOV-GP, rVSV, V920, Placebo, rVSV boost
National Institute of Allergy and Infectious Diseases (NIAID), Partnership for Research on Ebola Virus in Liberia (PREVAIL), Institut National de la Santé Et de la Recherche Médicale, France, London School of Hygiene and Tropical Medicine, European and Developing Countries Clinical Trials Partnership (EDCTP)
Ebola Virus Disease
12/19
12/23
NCT05064956: Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)

Completed
2
26
RoW
Ad26.ZEBOV, Zabdeno®
London School of Hygiene and Tropical Medicine
Ebola Virus Disease, Ebola, Hiv
11/21
10/22
NCT05284097: Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Active, not recruiting
2
133
RoW
Ad26.ZEBOV, MVA-BN-Filo, VAC52150
London School of Hygiene and Tropical Medicine, University of Sierra Leone, Janssen Vaccines & Prevention B.V.
Virus Diseases, Hemorrhagic Fever, Ebola, Infections, Hemorrhagic Fevers, Viral, RNA Virus Infections, Filoviridae Infections, Mononegavirales Infections, Vaccines, Immunologic Factors, Physiological Effects of Drugs, Ebola
12/23
05/24
NCT03820739: EBOVAC-Salone Extension

Completed
N/A
653
RoW
Follow-up, Blood sample collection
London School of Hygiene and Tropical Medicine, University of Sierra Leone, Janssen Vaccines & Prevention B.V., Institut National de la Santé Et de la Recherche Médicale, France, Universiteit Antwerpen
Ebola Virus Disease
06/22
07/22

Download Options